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Chapter 8: AMACING societal and scientific impact  ʹͲ͵ 
8. AMACING societal and scientific impact 
Every day, hundreds of thousands procedures with intravascular iodinated contrast 
injections are carried out the world over (CT scans, coronary angiographies, etc.).2 
Many of these procedures are performed in elderly patients with cardiovascular 
disease, decreased renal function, diabetes mellitus, and on nephrotoxic medication, 
all risk factors for post-contrast renal injury. Weighing the benefits against the risks 
of contrast injections is something health care professionals from all specialties are 
confronted with daily.  
 
Guidelines on safe use of iodinated contrast material recommend intravenous 
prophylactic hydration to prevent post-contrast adverse (renal) effects.70-73,76 The 
AMACING trial  - an interdisciplinary collaboration between the departments 
Radiology, Cardiology, Internal Medicine, Clinical Epidemiology & Medical 
Technology Assessment of Maastricht University Medical Centre, and Epidemiology 
of Maastricht University - is the first and only study to show that prophylactic 
intravenous hydration is not (cost-) effective for the largest part of the population 
eligible for prophylaxis according to the evaluated guideline. The conclusions were 
confirmed by the 1-year follow-up data.104,105 The consequences of the AMACING 
findings are profound. 
 
The AMACING trial prompted an amendment to several guidelines: clinical practice 
has been demonstrably altered in the Netherlands and Europe, and the impact is felt 
worldwide.70-73,76-79 The guideline committees of the Netherlands (NVvR) and the 
United Kingdom (NICE) carried out exceptional reviews in order to incorporate 
AMACING trial findings into their guidelines: that routine use of prophylactic 
intravenous hydration in at-risk patients with eGFR 30-59 ml/min/1.73m2 may not be 
beneficial and may inadvertently cause harm through fluid overload.76,77  
 
At this time most guidelines have been updated in line with the AMACING trial 
results. In Europe, America and Ocenia, umbrella organisations no longer 
recommend standard prophylaxis for patients with estimated glomerular filtration 
rate (eGFR) 30-59 ml/min/1.73m2 combined with risk factors represented by 
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AMACING trial participants.70,71,73,79 The chages in recommendations on standard 
prophylaxis in the Dutch (The Radiological Society of The Netherlands, NVvR) 
guidelines are detaied in table 8.1.76 The updates have led to palpable changes for 
patients, hospitals and health care budgets, and has promoted a paradigm shift in 
the scientific discussion surrounding CIN and iodinated contrast material 
administration. 
 
 
8.1 Local effects: Maastricht UMC+ 
At Maastricht UMC+ the protocol for the prevention of CIN was updated and 
implemented in the summer of 2017. After the in-house protocol had been updated 
to no longer giving prophylaxis to those patients with eGFR 30-59 ml/min/1.73m2 
formerly eligible for prophylaxis, the observational Contrast-Induced Nephropathy 
After Reduction of the prophylaxis Threshold (CINART) project was started 
(registered with Clinicaltrials.gov under NCT03227835).191 The aim of this 
retrospective observational study was to evaluate consequences for clinical practice 
at Maastricht University Medical Centre (UMC+) in terms of patient burden 
(complications of prophylaxis), hospital burden (extra hospitalisations for 
prophylaxis), and costs.  
 
In this project, retrospective data similar to data collected prospectively for the 
AMACING trial were registered on all elective procedures with intravascular 
iodinated contrast administration in patients formerly eligible for prophylaxis (with 
eGFR 45-59 ml/min/1.73m2 in combination with diabetes or more than 1 risk factor, 
OR with eGFR 30-44 ml/min/1.73m2)70,75, and in patients currently eligible for 
prophylaxis (with eGFR <30 ml/min/1.73m2).76,78  
 
The data concern procedures, therefore repeat inclusion of patients was allowed. 
Data were retrospectively collected from patient electronic files. The Medical 
Research Ethics Committee Maastricht UMC+ waived the requirement for informed 
consent. 
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The primary outcome was the number of elective radiology or cardiology procedures in 
patients (no longer) eligible for standard prophylaxis, i.e. the number of procedures in 
patients formerly eligible for standard prophylaxis, according to guidelines before the 
update, and the number of procedures in patients currently eligible for standard 
prophylaxis, according to updated guidelines. Additional information concerns the 
proportions of outpatients, defined as the proportion of patients not hospitalised at 
the moment of referral for the contrast procedure.  
 
The results were subsequently used to calculate the main results: the impact of 
guideline updates in terms of relative reduction in the numbers of complications, 
hospitalisations, and costs associated with prophylactic intravenous hydration. 
 
 
 
Table 8.1. Clinical practice recommendations for elective patients in the Netherlands 
before and after guideline updates 
Guideline 
recommendation§ 
Before  
November 2017 update 
    After  
November 2017 update 
Patient eligible for 
standard 
prophylaxis 
- eGFR <45 ml/min/1.73m2 
or eGFR 45-59 ml/min/1.73m2 
combined with diabetes or >1 
risk factor$ 
eGFR <30 ml/min/1.73m2 
Standard 
prophylaxis 
iv 0.9% NaCl 4 or 12 h before 
& 4 or 12 h after  
iv 1.4% NaHCO3 1 h before (& 
6 h after)  
eGFR = estimated glomerular fitration rate. §Centraal Begeleidings Orgaan guideline on 
iodinated contrast material 2007,75 and The Radiological Society of The Netherlands (RSTN - 
NVvR)76 guideline on safe use of contrast media 2017; $age >75 years, anaemia, cardiovascular 
disease, nephrotoxic medication. 
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From July 1, 2017 until July 1, 2018, a total of 1 992 elective procedures with 
intravascular iodinated contrast material in patients formerly and currently eligible for 
prophylaxis were identified: 1 808 procedures in patients formerly eligible for 
prophylaxis (with eGFR 30-59 ml/min/1.73m2 combined with risk factors), and 184 
procedures in patients with eGFR <30 ml/min/1.73m2 currently eligible for prophylaxis 
(figure 8.1).  
 
Calculations of complications, hospitalisations, and costs associated with standard 
prophylaxis before and after guideline updates are detailed below and the findings are 
illustrated in figure 8.2.  
 
 
 
 
Figure 8.1. Screening and inclusion profile of the CINART study 
CECT = contrast-enhanced computed tomography; CAG = coronary angiography; PCI = 
percutaneous coronary intervention; TAVI = transcatheter aortic valve implantation. *i.e. eGFR 
30-59 ml/min/1.73m2 combined with risk factors; $i.e. eGFR <30 ml/min/1.73m2 
 
  
22.660 elective procedures at Maastricht UMC+ (excluding emergency & intensive care) 
 from July 1, 2017 to July 1, 2018  
Ð 
13.182 elective procedures with intravascular iodinated contrast 
 (10 015 CECT; 877 peripheral intervention; 170 angiography; 1.677 CAG/PCI; 191 TAVI; 252 other) 
 
Ð 
1.808 procedures in patients formerly eligible for prophylaxis* 
184 procedures in patients currently eligible for prophylaxis$ 
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CALCULATIONS 
Complications of prophylaxis  
The number of complications of prophylaxis was calculated based on the 5.5% rate of 
complications found in AMACING trial patients with eGFR 30-59 ml/min/1.73m2 
combined with risk factors (Chapter 2), and the 6.4% rate of complications found in our 
4-year observational study in patients with eGFR <30 ml/min/1.73m2 (Chapter 6).104,135  
 
Total complications before update: (1 808*0.055) + (184*0.064) = 111/year 
Total complications after update: 184*0.064 = 12/year 
Total complications avoided after guideline update: 0.055*1 808 = 99/year (-89%) 
 
 
Hospitalisation for prophylaxis  
CINART registered 85.4% outpatients (1.544/1.808) in the group formerly eligible for 
prophylaxis, and 64.7% outpatients in the group currently eligible for prophylaxis 
(119/184).  
 
Total extra hospitalisations before update: (1 808*0.854) + (184*0.647) = 1 663/year 
Total extra hospitalisations after update: 184*0.647 = 119/year 
Total beds freed after the guideline update: 1 808*0.854 = 1 544/year (-93%) 
 
 
Costs  
Cost calculations were based on the difference in costs associated with elective 
contrast procedures (excluding costs of the procedure itself) up to one month post-
contrast as registered in the AMACING trial:104 mean extra costs of resources used by 
patients receiving standard prophylaxis were €663 per procedure per patient. These 
costs were mostly due to hospitalisation costs. 
 
Total extra costs before the guideline update: 1 992*€663 = €1 320 696/year 
Total extra costs after the guideline update: 184*€663  = €121 992/year  
Total savings after the guideline update: €1 198 704/year (-91%) 
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1 320 696 1 663 111 
121 992 119 12 
Abolishing prophylaxis for patients with eGFR 30-59 ml/min/1.73m2 combined with 
risk factors and administering it only to patients with eGFR <30 ml/min/1.73m2 has led 
to an estimated 89% reduction in the number of patients suffering complications of 
prophylaxis such as symptomatic heart failure (99 cases a year); 93% reduction in the 
number of hospitalisations for prophylaxis (1 544 a year); and 91% reduction in medical 
costs (€ 1.2 million a year) at Maastricht UMC+.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2. Costs, hospitalisations, and complications associated with standard 
prophylaxis at Maastricht UMC+ before and after guideline updates  
 
 
-1.2 million/year  
(՝ 91%) 
-1 544 /year  
(՝ 93%) 
-99/year  
(՝ 89%) 
after 
update 
     EXTRA COSTS      HOSPITALISATION                         COMPLICATIONS 
         (€/year)         (patients/year)              (patients/year) 
before 
update 
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8.2 (Inter)national effects 
It is estimated that the updated recommendations for prophylaxis save up to 50 to 100 
million euro each year in the Netherlands alone.104 At the same time hospital bed 
occupancy has been drastically reduced and complications are avoided, relieving 
patient and hospital burden. 
 
A world impact estimate can be acgueved using calculations as in CINART (detailed 
under section 8.1 above), although one must adjust for lower adherence to guideline 
recommendations. Guideline recommendations were imposed quite strictly in the 
Netherlands which is why adherence is close to 100%, but experience and surveys have 
shown that elsewhere adherence may be absent (e.g. a hospital in China and a hospital 
in France; personal communication) or somewhere at the level of 64-87%.163  
 
Based on the estimated number of iodinated contrast injections carried out worldwide 
– estimated at 75 million a year in 20052 – and assuming a worldwide average 
adherence to guideline recommendations of 40% (based on the reported 64-87% 
adherence in Europe, Oceania and North America, and a worst-case scenario of zero 
adherence in Africa, South America, and half of Asia), the results estimate would be 
that over 225 000 patients a year no longer suffer complications such as symptomatic 
heart failure associated with the prophylactic treatment, that over 3.5 million patients 
need no longer be hospitalized for prophylaxis, and that savings for health care budgets 
are over €2.7 billion, each year.  
 
[Note that in these estimations, the number of intravascular injections dates from the 
year 2005, and the costs are indexed to 2015.] 
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8.3 Scientific discussion 
Besides these societal and individual effects, AMACING has rekindled and changed the 
scientific discussion around CIN, prophylaxis and clinical practice guidelines. The 
widespread interest in the subject is reflected in the myriad conference presentations 
and workshops that have been given by third parties on AMACING, the various 
editorials in prominent journals, the many medical blogs and news items, and the >1 
million followers on Twitter (see Appendix I for an overview and QR access codes). 
Furthermore, a double publication in Dutch was requested by the Nederlands 
Tijdschrift voor Geneeskunde (see Appendix II for the full article), a reprint in Chinese 
was produced by the Lancet, and letters were written to editors of medical journals 
other than the Lancet, one of which invited us to respond (see keypoints and the full 
letter in Appendix III).  
 
Not surprisingly, the Lancet article received much attention: PlumXmetrics has so far 
registered a citation index of 111, and according to Altmetric the article has received 
more attention than 95% of all publications they have tracked (see Appendix I, 
numbers 19 & 20). Three Dutch medical professional associations (the Cardiology, 
Internal Medicine, and Radiological Societies) have nominated AMACING for the 2019 
Dutch Association of Medical Specialists Science & Innovation Research Award. 
 
The AMACING publications have contributed toward the fact that guideline-
recommendations not backed by scientific evidence are more openly questioned, risk 
of prophylactic intravenous hydration is given more of the recognition it deserves, and 
risk of elective iodinated contrast administration is re-evaluated (Appendix I gives links 
and QR access codes to editorials, news items, tweets, and blogs).  
 
Dr. Mandrola, Medscape:134 “Results of the AMACING study force us to 1) be 
suspicious of expert opinion, 2) object to quality measures not backed by randomized 
trial data, and 3) reconsider the existence of an entire disease entity (CIN), and in 
doing so, think about how our brains can trick us into seeing signal when there is 
mostly noise.” 
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In the more recent publications on patients with eGFR <30 ml/min/1.73m2 the 
discussion is taken even further, introducing the questions whether preventive 
measures may sometimes be worse than doing nothing, and whether current clinical 
practice gives sufficient room for individualized precision medicine.128,135 These two 
papers have led to changes in clinical practice too. 
 
 
8.4 Effects for eGFR <30 ml/min/1.73m2 patients  
At Maastricht UMC+ we have translated the results into a new protocol for the 
prevention of complications of prophylaxis and post-contrast renal events. Patients 
with eGFR<30 ml/min/1.73m2 are especially vulnerable, and their relatively low 
numbers enable us to give them extra attention. In order to do so, a new unit has been 
set up in December 2018: the Contrast Voorbereidings Poli (CVP) Maastricht UMC+. 
The first aim of this unit is to prevent serious complications of prophylactic intravenous 
hydration and eliminate associated deaths. The second aim is to provide 100% post-
contrast follow-up of renal function.  
 
Thus, all elective patients with eGFR <30 ml/min/1.73m2 are seen at the CVP before a 
contrast procedure, and their cardiac parameters are evaluated in order to determine 
whether prophylactic treatment can be given. Second, the renal function of all patients 
with eGFR <30 ml/min/1.73m2, elective or emergent, who receive intravascular 
iodinated contrast is checked 2-5 days post-contrast. 
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